Fate Therapeutics Inc [NASDAQ: FATE] gained 12.38% on the last trading session, reaching $2.27 price per share at the time.
If compared to the average trading volume of 1.26M shares, FATE reached a trading volume of 24725999 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Here is what top equities market gurus are saying about Fate Therapeutics Inc [FATE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FATE shares is $6.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FATE stock is a recommendation set at 2.65. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Fate Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on Nov-19-24. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $4 to $6. The new note on the price target was released on June 17, 2024, representing the official price target for Fate Therapeutics Inc stock. Previously, the target price had yet another raise to $6, while Wells Fargo analysts kept a Equal Weight rating on FATE stock. On January 24, 2023, analysts decreased their price target for FATE shares from 115 to 7.
The Average True Range (ATR) for Fate Therapeutics Inc is set at 0.32, with the Price to Sales ratio for FATE stock in the period of the last 12 months amounting to 18.67. The Price to Book ratio for the last quarter was 0.71, with the Price to Cash per share for the same quarter was set at 2.68.
Trading performance analysis for FATE stock
Fate Therapeutics Inc [FATE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.33. With this latest performance, FATE shares dropped by -29.72% in over the last four-week period, additionally sinking by -41.94% over the last 6 months – not to mention a drop of -4.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FATE stock in for the last two-week period is set at 39.68, with the RSI for the last a single of trading hit 41.18, and the three-weeks RSI is set at 39.52 for Fate Therapeutics Inc [FATE]. The present Moving Average for the last 50 days of trading for this stock 3.09, while it was recorded at 2.18 for the last single week of trading, and 4.46 for the last 200 days.
Fate Therapeutics Inc [FATE]: A deeper dive into fundamental analysis
Fate Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.29 and a Current Ratio set at 8.29.
Fate Therapeutics Inc [FATE]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Fate Therapeutics Inc posted -0.45/share EPS, while the average EPS was predicted by analysts to be reported at -0.5/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.05. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FATE.
An analysis of Institutional ownership at Fate Therapeutics Inc [FATE]
There are presently around $102.09%, or 104.35%% of FATE stock, in the hands of institutional investors. The top three institutional holders of FATE stocks are: REDMILE GROUP, LLC with ownership of 13.17 million shares, which is approximately 13.0252%. VANGUARD GROUP INC, holding 10.57 million shares of the stock with an approximate value of $$34.67 million in FATE stocks shares; and VANGUARD GROUP INC, currently with $$33.18 million in FATE stock with ownership which is approximately 10.0056%.
